Caris Introduces New Breast Cancer Signature in Tumor Profiling Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy CAI?
Source: PRnewswire
- New Signature Launch: Caris Life Sciences has introduced a new breast cancer signature in its Molecular Tumor Board Report, utilizing over 2,000 expression and copy number features to predict response to capecitabine in HER2-negative breast cancer patients, thereby enhancing the precision of personalized treatment.
- AI-Driven Insights: The Caris AI Insights section of the report leverages artificial intelligence and clinico-genomic data to provide researchers and clinicians with a valuable molecular blueprint of a patient's tumor biology, further advancing the development of precision medicine.
- FDA-Approved Innovation: Caris received FDA approval in 2024 for MI Cancer Seek, the first assay combining Whole Exome and Whole Transcriptome Sequencing for molecular profiling, marking the company's leadership in tumor molecular characterization.
- Global Market Expansion: With headquarters in Texas and offices in multiple global cities, Caris is committed to promoting the adoption of precision medicine through its innovative solutions, thereby enhancing its competitive position in the biotechnology industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAI
Wall Street analysts forecast CAI stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.770
Low
30.00
Averages
36.17
High
40.00
Current: 17.770
Low
30.00
Averages
36.17
High
40.00
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Caris Develops Predictive Model for Glioblastoma Therapy Selection
- Advancement in GBM Treatment: Caris Life Sciences announced the development of a predictive model for therapy selection in glioblastoma patients, created from clinical-genomic data of 5,841 patients, aimed at improving prediction accuracy for chemotherapy responses and thereby enhancing patient survival rates.
- AI Model Benefits: The AI model effectively infers the O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status from MI cancer Seek NGS assay data, providing better overall survival predictions, particularly for patients treated with temozolomide (TMZ).
- Clinical Validation Data: The model's success rate was evaluated using a cohort of 3,400 GBM cases, demonstrating its potential in clinical applications, especially for the over half of patients who do not respond to TMZ, aiding physicians in formulating more effective treatment plans.
- Market Reaction: Although Caris Life Sciences' stock is currently trading at $17.93, down 2.77%, the release of this technology may attract investor interest due to its innovative potential in the precision medicine sector.
See More
Caris Launches New Predictive Model for Glioblastoma Therapy Selection
- New Predictive Model: Caris Life Sciences has announced the development of a new predictive model aimed at guiding therapy selection for over 5,800 glioblastoma patients, validated through peer review in Neuro-Oncology Advances, showcasing significant clinical application potential.
- Survival Rate Improvement: The model effectively predicts O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status by analyzing clinical and genomic data, assisting physicians in better assessing patient responses to temozolomide (TMZ) treatment, thereby enhancing patient survival rates.
- Clinical Application Prospects: Evaluated in over 3,400 prospective cases, the model demonstrated that patients with higher scores had significantly longer survival times after TMZ treatment, further validating its importance in clinical decision-making.
- Technological Integration Advantage: By leveraging its proprietary CodeAI™ platform to integrate various real-world datasets, Caris is advancing precision oncology, demonstrating the company's innovative capabilities in cancer treatment, which is expected to have a profound impact on future cancer therapies.
See More
Caris Launches New Predictive Model for Glioblastoma Therapy Selection
- New Predictive Model: Caris Life Sciences announced the development of a new predictive signature, validated through peer review, aimed at guiding therapy selection for over 5,800 glioblastoma patients, marking a significant advancement in precision medicine.
- Biomarker Assessment: The model infers O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status from NGS data, an important biomarker associated with response to TMZ therapy, enhancing the accuracy of clinical decision-making.
- Survival Stratification: In a prospective evaluation of over 3,400 patients, the model successfully stratified patients into distinct survival groups, with higher signature scores correlating with significantly longer overall survival in TMZ-treated patients, demonstrating its clinical application potential.
- Technological Integration Advantage: By integrating multimodal real-world datasets with its proprietary CodeAI™ platform, Caris advances precision oncology, further enhancing its competitive edge and market position in the cancer treatment field.
See More
Caris Life Sciences to Present at Two Major Healthcare Conferences
- Conference Schedule: Caris Life Sciences will present at the BofA Securities Healthcare Conference in Las Vegas on May 12, 2026, from 10:00 to 10:30 AM PT, showcasing its latest advancements in precision medicine.
- Global Healthcare Conference: Additionally, Caris will speak at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8, 2026, from 10:40 to 11:15 AM ET, further enhancing its industry influence.
- Technological Innovation: Caris is committed to developing precision medicine solutions through comprehensive molecular profiling and advanced AI technologies, driving transformation in early detection and therapy selection, thereby demonstrating its leadership in the health tech sector.
- Global Presence: With services offered in the U.S. and international markets, and offices in locations such as Tokyo, Japan, and Basel, Switzerland, Caris emphasizes its global strategy and commitment to international markets.
See More
Caris Life Sciences to Present at Two Major Healthcare Conferences
- Conference Participation: Caris Life Sciences will participate in the BofA Securities Healthcare Conference from May 12-14, 2026, in Las Vegas, and the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10, 2026, in Miami, showcasing its advancements in precision medicine.
- Presentation Schedule: At the BofA conference, Caris will present on May 12 from 10:00 to 10:30 AM PT, and at the Goldman Sachs conference, the presentation is scheduled for June 8 from 10:40 to 11:15 AM ET, which is expected to attract attention from investors and industry experts.
- Technological Innovation: Caris is committed to developing precision medicine solutions through comprehensive molecular profiling and advanced AI technologies, aiming to improve early disease detection and treatment options, thereby transforming the healthcare industry.
- Global Presence: With offices in Texas, Arizona, New York, Cambridge, Tokyo, and Basel, Caris provides services in the U.S. and international markets, demonstrating its strategic intent to expand in the global precision medicine market.
See More
Caris Life Sciences to Report Q1 2026 Financial Results on May 7
- Earnings Announcement: Caris Life Sciences will report its Q1 2026 financial results on May 7, 2026, and will host a live webcast at 3:30 p.m. CT to provide insights into its financial performance to investors.
- Webcast Details: The webcast will be accessible via the Caris Life Sciences website, allowing investors to view a replay shortly after the call, ensuring timely communication and transparency of information.
- Company Overview: Caris Life Sciences is a leading patient-centric next-generation AI TechBio company focused on precision medicine, actively developing and commercializing innovative solutions to transform healthcare.
- Technological Edge: By leveraging comprehensive molecular profiling and advanced AI technologies, Caris has created a large-scale clinico-genomic database aimed at analyzing the molecular complexity of diseases, thereby advancing precision medicine diagnostic solutions.
See More
Caris Develops Predictive Model for Glioblastoma Therapy Selection
- Advancement in GBM Treatment: Caris Life Sciences announced the development of a predictive model for therapy selection in glioblastoma patients, created from clinical-genomic data of 5,841 patients, aimed at improving prediction accuracy for chemotherapy responses and thereby enhancing patient survival rates.
- AI Model Benefits: The AI model effectively infers the O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status from MI cancer Seek NGS assay data, providing better overall survival predictions, particularly for patients treated with temozolomide (TMZ).
- Clinical Validation Data: The model's success rate was evaluated using a cohort of 3,400 GBM cases, demonstrating its potential in clinical applications, especially for the over half of patients who do not respond to TMZ, aiding physicians in formulating more effective treatment plans.
- Market Reaction: Although Caris Life Sciences' stock is currently trading at $17.93, down 2.77%, the release of this technology may attract investor interest due to its innovative potential in the precision medicine sector.
See More
Caris Launches New Predictive Model for Glioblastoma Therapy Selection
- New Predictive Model: Caris Life Sciences has announced the development of a new predictive model aimed at guiding therapy selection for over 5,800 glioblastoma patients, validated through peer review in Neuro-Oncology Advances, showcasing significant clinical application potential.
- Survival Rate Improvement: The model effectively predicts O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status by analyzing clinical and genomic data, assisting physicians in better assessing patient responses to temozolomide (TMZ) treatment, thereby enhancing patient survival rates.
- Clinical Application Prospects: Evaluated in over 3,400 prospective cases, the model demonstrated that patients with higher scores had significantly longer survival times after TMZ treatment, further validating its importance in clinical decision-making.
- Technological Integration Advantage: By leveraging its proprietary CodeAI™ platform to integrate various real-world datasets, Caris is advancing precision oncology, demonstrating the company's innovative capabilities in cancer treatment, which is expected to have a profound impact on future cancer therapies.
See More
Caris Launches New Predictive Model for Glioblastoma Therapy Selection
- New Predictive Model: Caris Life Sciences announced the development of a new predictive signature, validated through peer review, aimed at guiding therapy selection for over 5,800 glioblastoma patients, marking a significant advancement in precision medicine.
- Biomarker Assessment: The model infers O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status from NGS data, an important biomarker associated with response to TMZ therapy, enhancing the accuracy of clinical decision-making.
- Survival Stratification: In a prospective evaluation of over 3,400 patients, the model successfully stratified patients into distinct survival groups, with higher signature scores correlating with significantly longer overall survival in TMZ-treated patients, demonstrating its clinical application potential.
- Technological Integration Advantage: By integrating multimodal real-world datasets with its proprietary CodeAI™ platform, Caris advances precision oncology, further enhancing its competitive edge and market position in the cancer treatment field.
See More
Caris Life Sciences to Present at Two Major Healthcare Conferences
- Conference Schedule: Caris Life Sciences will present at the BofA Securities Healthcare Conference in Las Vegas on May 12, 2026, from 10:00 to 10:30 AM PT, showcasing its latest advancements in precision medicine.
- Global Healthcare Conference: Additionally, Caris will speak at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8, 2026, from 10:40 to 11:15 AM ET, further enhancing its industry influence.
- Technological Innovation: Caris is committed to developing precision medicine solutions through comprehensive molecular profiling and advanced AI technologies, driving transformation in early detection and therapy selection, thereby demonstrating its leadership in the health tech sector.
- Global Presence: With services offered in the U.S. and international markets, and offices in locations such as Tokyo, Japan, and Basel, Switzerland, Caris emphasizes its global strategy and commitment to international markets.
See More
Caris Life Sciences to Present at Two Major Healthcare Conferences
- Conference Participation: Caris Life Sciences will participate in the BofA Securities Healthcare Conference from May 12-14, 2026, in Las Vegas, and the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10, 2026, in Miami, showcasing its advancements in precision medicine.
- Presentation Schedule: At the BofA conference, Caris will present on May 12 from 10:00 to 10:30 AM PT, and at the Goldman Sachs conference, the presentation is scheduled for June 8 from 10:40 to 11:15 AM ET, which is expected to attract attention from investors and industry experts.
- Technological Innovation: Caris is committed to developing precision medicine solutions through comprehensive molecular profiling and advanced AI technologies, aiming to improve early disease detection and treatment options, thereby transforming the healthcare industry.
- Global Presence: With offices in Texas, Arizona, New York, Cambridge, Tokyo, and Basel, Caris provides services in the U.S. and international markets, demonstrating its strategic intent to expand in the global precision medicine market.
See More
Caris Life Sciences to Report Q1 2026 Financial Results on May 7
- Earnings Announcement: Caris Life Sciences will report its Q1 2026 financial results on May 7, 2026, and will host a live webcast at 3:30 p.m. CT to provide insights into its financial performance to investors.
- Webcast Details: The webcast will be accessible via the Caris Life Sciences website, allowing investors to view a replay shortly after the call, ensuring timely communication and transparency of information.
- Company Overview: Caris Life Sciences is a leading patient-centric next-generation AI TechBio company focused on precision medicine, actively developing and commercializing innovative solutions to transform healthcare.
- Technological Edge: By leveraging comprehensive molecular profiling and advanced AI technologies, Caris has created a large-scale clinico-genomic database aimed at analyzing the molecular complexity of diseases, thereby advancing precision medicine diagnostic solutions.
See More
